Endocrinology Advisor2d
Oral Semaglutide Elicits Superior Cardiometabolic Effects in T2D
Oral semaglutide demonstrated superior cardiometabolic outcomes relative to placebo and active comparators, including empaglifozin, in T2D.
New Scientist3d
Ozempic weight loss is deemed less praiseworthy than lifestyle changes
People seem to be less impressed when others lose weight with the drug Ozempic than when they achieve it via lifestyle ...
Medscape4d
GLP-1s and Joint Surgery: Mixed Picture
The effect of glucagon-like peptide 1 receptor agonists on patients with joint infections was a popular topic at the American ...
Semaglutide boosts walking ability in diabetes patients with peripheral artery disease, clinical trial finds
Semaglutide, a glucagon-like peptide 1 (GLP-1) agonist, significantly improved maximal walking distance in people with ...
1NVO : Novo Nordisk Shares Data From Injectable Ozempic, Oral Weight Loss Drug
Novo Nordisk's Phase 3b STRIDE trial shows Ozempic improves walking distance in peripheral artery disease, while the SOUL ...
Semaglutide 2.4 mg reduces burden of total cardiovascular events in people with established cardiovascular disease and overweight or obesity
A new sub-analysis of the SELECT trial data shows semaglutide 2.4 mg substantially reduces the burden of total cardiovascular ...
Semaglutide: A Cardiovascular Game-Changer
Not only does it combat diabetes and aid in weight loss, but it also safeguards heart health in all patients at high ...